In This Article:
-
Aridis Pharmaceuticals Inc (NASDAQ: ARDS) has announced that its COVID-19 mAb cocktail AR-712 binds and neutralizes the Delta variant of COVID-19 at a highly effective level (~20ng/mL).
-
Binding analyses project that AR-712 will be effective against all variants on the U.S. CDC's variants of interest and concern lists.
-
The dual antibody cocktail will be delivered as an inhaled treatment and is expected to provide broad coverage of all known high-risk variants.
-
In addition, Aridis announced preclinical development services support from NIAID (NIH) after demonstrating a robust therapeutic efficacy of inhaled delivery in a SARS-CoV-2 hamster challenge model.
-
This achieved reversal of disease in infected animals at an inhaled dose of 1mg/kg, equivalent to a 10mg dose in humans from a nebulizer. For reference purposes, the dose of commercially available COVID antibody therapies is currently in the range of 500mg to 1,200mg.
-
AR-712 is being developed as a self-administered, at-home inhaled treatment for COVID-19 patients who are not yet hospitalized.
-
The Company remains on track to finalize the Phase 1/2/3 design for this program and initiate the clinical study in 2H 2021.
-
AR-712 is a cocktail of two fully human immunoglobulin G1 (IgG1) mAbs discovered from screening the antibody-secreting B-cells of convalescent COVID-19 infected patients.
-
Price Action: ARDS shares are down 4.3% at $6.99 during the premarket session on the last check Tuesday.
See more from Benzinga
-
Biogen, InnoCare Collaborate On Multiple Sclerosis Candidate
-
PLx Pharma Stock Jumps As Its Liquid-Filled Aspirin Capsule Will Now Be Available At Walmart
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.